AFP & AFP-L3

Liver cancer, specifically a type called hepatocellular carcinoma (HCC), is one of the fastest-rising causes of cancer death worldwide. It usually develops silently inside a liver already damaged by years of hepatitis, fatty liver disease, or heavy alcohol use. By the time symptoms appear, the tumor is often advanced. Catching it early, when curative treatment is still possible, depends almost entirely on screening.

This panel pairs two blood markers that work as a team. One measures the total amount of a protein your liver makes when cells are growing abnormally. The other measures the specific fraction of that protein most closely tied to cancer. Together, they answer a question that neither test can answer alone: is this protein elevation coming from cancer, or from the chronic liver damage that preceded it?

What This Panel Reveals

Alpha-fetoprotein (AFP) is a protein normally produced in large quantities by a developing fetus. In healthy adults, AFP circulates at very low levels. When liver cells begin multiplying abnormally, whether from regeneration after injury or from a growing tumor, AFP levels can rise. A single AFP reading above 20 ng/mL (a standard unit of concentration in blood testing) has been associated with HCC, but the same elevation can also appear in people with active hepatitis flares or advancing cirrhosis (severe liver scarring) who have no tumor at all.

That overlap is the core problem with AFP alone. In a large prospective study of patients with hepatitis C and advanced fibrosis (significant liver scarring), AFP at a cutoff of 20 ng/mL detected about 59% of early-stage liver cancers while correctly ruling out cancer in roughly 90% of those without it. That means roughly 4 in 10 early cancers were missed, and some people without cancer were falsely flagged.

AFP-L3 solves part of this problem. AFP exists in three sugar-coated forms, each binding differently to a plant protein called lens culinaris agglutinin (LCA). The L3 fraction binds most tightly to LCA and is produced preferentially by malignant liver cells rather than by benign, regenerating ones. When AFP-L3 is expressed as a percentage of total AFP, an AFP-L3% above 10% shifts the probability sharply toward cancer, even when total AFP is only mildly elevated.

Why the Combination Matters More Than Either Test Alone

Total AFP tells you something is happening in the liver. AFP-L3% tells you whether that something is likely cancer. A person with cirrhosis whose AFP drifts up to 30 ng/mL could be experiencing a hepatitis flare or early tumor growth. If their AFP-L3% is 3%, the elevation is more likely benign. If it is 15%, the probability of HCC rises substantially.

In a study of patients with chronic hepatitis C and advanced liver disease, adding AFP-L3% to total AFP improved the ability to distinguish early HCC from cirrhosis without cancer. AFP-L3% also helps predict how aggressive a tumor may be: elevated levels have been linked to tumors that grow into nearby blood vessels and have less organized cell structure, both of which affect treatment options and outcomes.

A scoring system called GALAD (which combines Gender, Age, AFP-L3, AFP, and des-gamma-carboxy prothrombin) has correctly identified more than 80% of early-stage HCC cases in validation studies. While this panel does not include all GALAD components, AFP and AFP-L3% supply two of its three laboratory inputs and form the foundation of that model.

How to Read Your Results Together

The value of this panel is in the pattern, not in either number by itself. Here are the main scenarios you may encounter:

An important caveat: AFP-L3% is most reliable when total AFP is above approximately 10 ng/mL. At very low total AFP levels, the percentage calculation can be less precise, though newer highly sensitive assays have improved measurement at lower AFP concentrations.

When Results Can Be Misleading

Several conditions can raise total AFP without cancer being present. Active viral hepatitis (particularly hepatitis B flares), pregnancy, and certain tumors of the reproductive organs (called germ cell tumors) all produce AFP elevations. In these settings, AFP-L3% helps, but it is not infallible. Acute hepatitis flares can transiently raise AFP-L3% in a small number of cases.

Conversely, not all liver cancers produce AFP. Roughly 30% to 40% of HCC cases present with normal AFP, particularly small, early-stage, and well-differentiated tumors. A normal AFP and AFP-L3% result does not rule out liver cancer. Imaging surveillance with ultrasound or MRI remains the primary screening tool, and this panel works best as a complement to imaging, not a replacement.

Tracking Over Time

A single AFP and AFP-L3% draw is a snapshot. Serial testing every 6 months transforms that snapshot into a trend, and the trend is where the real power lies. A steadily rising AFP, even within the "normal" range, combined with a creeping AFP-L3% from 4% to 8% to 12% over successive draws, can signal a developing tumor months before it becomes visible on ultrasound.

Longitudinal tracking also helps after treatment. After surgical removal or ablation (destruction of tumor tissue using heat or cold) of an HCC, a declining AFP and normalizing AFP-L3% suggest successful treatment. A subsequent rise in either marker can be the earliest sign of recurrence, often preceding imaging findings. The 2023 AASLD (American Association for the Study of Liver Diseases) Practice Guidance acknowledges AFP as part of HCC surveillance and supports serial biomarker monitoring in at-risk populations.

What to Do with Your Results

If both markers are normal and you have no known liver disease, your immediate liver cancer risk is very low. If you do have chronic liver disease, keep testing every 6 months alongside imaging.

If AFP is elevated but AFP-L3% is low, the priority is identifying the cause of AFP elevation. This usually means assessing liver inflammation with a liver function panel, checking viral hepatitis status, and ensuring your imaging surveillance is up to date.

If AFP-L3% is elevated (above 10%), regardless of total AFP level, you should get contrast-enhanced liver imaging (MRI or CT with special contrast dye) and see a hepatologist (liver specialist). Do not wait for the next routine screening interval. When AFP-L3% is elevated in someone with cirrhosis, the chance that cancer is present is high enough that delaying further evaluation is not appropriate.

Consider adding des-gamma-carboxy prothrombin (DCP, also called PIVKA-II) to future draws. DCP is the third biomarker in the GALAD model, and combining all three blood markers provides the strongest available blood-based detection of early HCC.